Tag: Cipla
Cipla launches Cippoint – a point-of-care device for non-communicable, infectious diseases
Point-of-Care solution to facilitate clinicians in quick and effective decision making
Cipla & Ethris partner for the development of mRNA-based therapies
The definitive agreements for equity investment of EUR 15 million in Ethris GmbH will fast-track Cipla’s participation in the mRNA space
Cipla increases its investment in GoApptiv, to soon hold 22.02% stake...
The company’s earlier investment in GoApptiv in June 2020 has yielded growth and expanded Cipla’s channel reach across lower tier towns in India
Cipla acquires 21.05% stake in Achira Labs to develop affordable medical...
This investment will facilitate a Cipla entity’s strategic participation in the PoC diagnostics and AMR space
Cipla & DNDi launch child-friendly 4-in-1 antiretroviral treatment in South Africa
This new formulation represents a significant improvement over protease inhibitor-containing paediatric ARV formulations that have been used in South Africa for decades
Cipla Launches ‘RT Direct’ Multiplex real time PCR kit for Covid-19
RNA extraction free kit to deliver results in just 45 minutes
Digitalization in pharma operations inevitable but challenges remain: Top CEOs
Industry captains and regulators in the ecosystem deliberate on achieving excellence and quality in operations, vaccine development and sustainability
CSIR-IICT to upskill students from North-Eastern states in a joint move
Indian Institute of Chemical Technology (IICT) will provide the students from the North-Eastern (NE) states with more advanced skills and training, jointly with Cipla, an Indian pharmaceutical company, headquartered in Mumbai.
Cipla to donate 5000 nebulizers to primary healthcare centres in India
Cipla launches initiative to improve access to nebulisers for acute asthma management in primary health care centres of rural India
Cipla ranked as one of most sustainable healthcare companies in DJSI
As of November 12, 2021, Cipla performed in the top decile in the pharmaceutical Industry in the S&P Global Corporate Sustainability Assessment, with a ranking of 93 percentile in the industry, meaning 93% of companies reached an equal or lower ESG Score..................